Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Was there news released ?
New interview out
Wow huge 583K share DUMP just now...
Agreed MS, time will tell. Certainly there should be significant developments on these fronts in the second half of 2018.
Law just passed we got to give them some time but yeah would love get cbd or cannabis update
Another day, another tweet about the VANC HIV Test. Although I appreciate the ethics of this product, I don't believe it will lead to share price appreciation. Maybe SP appreciation is not this company's goal?
Agreed 100% ceo is sleeping at the wheel
That would be nice. Im so bitter about this stock RN TBH. There's no excuse for not chasing down the pharmacy cannabis angle hard and fast. They should be releasing updates on their plans in that regard!
Would be nice to get a update now law passed they should know ...
If they can distribute or not .
Maybe they could start by proofreading their own twitter posts... Gotta be kidding me NUVPF....'securing technologies and and services'...
Wondering what our top three achievements have been so far? We break it down for you below, so have a look 👇$VANC #health #wellness pic.twitter.com/3tv3vojOZk
— Vancpharm (@Vanc_Pharm) June 20, 2018
Time to release some news. Senate passed, just formalities standing between us and legalization.
NUVPF trading sub $.15 is pathetic! These guys are killing me. Put me as CEO and I can get this stock to $1. SMFH
Tweets don't make up for SP in the gutter, NUVPF. Let's see you integrating endocannabinoid education into Healthtab and Corozon, please. This should be simple and should happen NOW! The opportunities to be the leader in educating the pharmacy world about the benefits of the endocannabinoid system is a real opportunity and it needs to be chased down with the utmost urgency. Focus needs to be on cannabis derivatives, extracts, concentrates - both CBD and THC, together and standalone. Do not even waste time thinking about actual flower, the entire game is going to be all about derivatives. NUVPF has a chance to become a thought leader in this emerging global industry, but if they don't move quickly someone else will. Please do NOT waste a golden opportunity NUVPF!!!!! LFG!
$VANC/NUVPF...love it. Drop the news that brings the chase. :)
I think we’re seeing the same things. Distribution for Emerald is a win/win/win. For Vanc, Emerald, and us.
VANC Bolsters Hema-Fer Market Presence with Amazon Canada Store Launch and Advertising Approvals
https://web.tmxmoney.com/article.php?newsid=6952172762594525&qm_symbol=VANC
The way I am reading the news about the iron supplement is essentially it looks like they are using their key specialty pharma product (iron supplement) as a base case to test their distribution network and branding plans. The goal of this should be to work out any issues or bottlenecks; then aggressively expand with EMH... imo
This is gonna to sneak up on people. Wait til they drop some extraction "product" news on us. It'll be too late for cheap then. :) $NUVPF/VANC
Thinking trying it for my wife !
Nice. Good to know they arent abandoning that product line.
Looks like they're gonna try and corner the market in iron deficiency supplements. :) Every $ counts! Bring on the MJ news. lol $NUVPF
VANCOUVER, British Columbia, June 05, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) is pleased to announce the launch of the Amazon Canada online store for Hema-Fer, along with Pharmaceutical Advertising Advisory Board (PAAB) approval of the Hema-Fer detail aid, and Advertising Standards Canada (ASC) approval of the newly-launched Hema-Fer website, www.hemafer.ca. Hema-Fer is the strongest over-the-counter (OTC) naturally derived heme iron polypeptide supplement available in Canada, and is indicated to help prevent iron deficiency and iron deficiency anemia.
“These developments will allow us to enrich the pharmaceutical knowledge base for healthcare professionals and their patients while strengthening VANC’s position as a leading provider of niche pharmaceuticals,” said Mark Kunzli, Executive Vice President at VANC. “This PAAB approved detail aid provides healthcare professionals with the clinical information they need to be confident recommending Hema-Fer to their patients.” The detail aid contains concise information on heme iron and ensures that healthcare professionals will be equipped to understand Hema-Fer’s uses and provide relevant information and recommendations to their patients. The PAAB is the only independent and not-for-profit organization recognized by Health Canada for the regulation of pharmaceutical product advertising to healthcare professionals.
VANC has also received ASC approval of the newly launched Hema-Fer website (www.hemafer.ca), designed to increase awareness and provide in-depth information for consumers to discuss Hema-Fer with their healthcare professional. The ASC is a self-regulating and not-for-profit advertising body responsible for maintaining accuracy and transparency in advertising by employing the Canadian Code of Advertising Standards. These approvals herald the launch of VANC Pharmaceutical’s Amazon Canada online store and website for Hema-Fer, allowing Canadians to conveniently purchase Hema-Fer and have it shipped to their home.
The Canadian iron supplement market is valued at $49 million annually, according to IQVIA 2017 data. To further bolster sales growth within this market, healthcare professionals will be provided with Hema-Fer promotional materials that will be distributed to pharmacies and medical clinics using VANC’s sales network. Pinnacle Pharmaceutics and their partners will employ 23 territory managers to carry out sales promotion of Hema-Fer in Ontario, Quebec and Atlantic Canada. Pinnacle is a leading sales and marketing agent for Canadian pharmaceutical manufacturers with a demonstrated track record proven by their service of 4,000 accounts nationally. Pinnacle’s sales team expertise will complement the existing sales promotion in Western Canada by The Zenar Group’s seven territory managers.
“The PAAB and ASC approvals build on our commitment to provide high-quality information to support our innovative and cost-effective over-the-counter products like Hema-Fer. We are also excited to provide Canadian consumers with direct access to Hema-Fer through our Amazon online store,” says Bob Rai, CEO and Director of VANC. “We believe this is a major step towards increasing Hema-Fer sales and we look forward to updating our investors with our progress over the coming quarters.”
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
www.vancpharm.com
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director and CEO
604-247-2639
info@vancpharm.com
www.vancpharm.com
Agreed! Excited to see if some major developments are coming our way. $NUVPF
Loving that they have and are building high quality activity on twitter, it is a GREAT indicator imho
Let's go $VANC/NUVPF...
https://twitter.com/Vanc_Pharm
Til then im adding nomnom nom
Law needs to pass , the they can apply for license !! Imho
These prices are so frustrating, can't believe it! Added a few more today. Will take a look at SEDAR here in a bit, thanks for the heads up.
YW! Let’s get this train moving. Lol
Check out SEDAR. VANC Mgmt Discussion & Analysis out. Lot of things right around the corner. $NUVPF
When EMH exercises those warrants, it's game on. Until then, it looks like it's all about playing the accumulation game. At least that's my approach, I will be adding next week if we are still down here.
Drop some news on us VANC. About time to make a move imo. $NUVPF
I like cheap lol
Not me. I like cheap shares. lol $NUVPF
Everyone going wait till they announce license to distribute !!! Lol chase mofos
Yes it is, Bring them bulls!! $NUVPF
Ready for the sector to get fired up. Our pipeline here is ready to make that $. $NUVPF
ICYMI — We executed a supply and distribution agreement with @EmeraldHealthHQ last month. We are going to work together to distribute medicinal #cannabis to Canadian pharmacies if they become authorized to do so by @GovCanHealth: https://t.co/cPjzu3aFH6 pic.twitter.com/xe4adXiynf
— Vancpharm (@Vanc_Pharm) May 19, 2018
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
307
|
Created
|
07/20/15
|
Type
|
Free
|
Moderators |
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) Board of Directors provided guidance on future company direction and initiatives today.
“In 2017 VANC had begun to anticipate secular changes affecting the generic and community pharmacy industries,” stated Mr. Bob Rai, CEO of VANC. “These changes included the trend towards increased funded participation by pharmacists in healthcare treatment of Canadians as well as dramatically shrinking margins on generic drugs. Our recent strategic partnerships, acquisitions and key personnel changes are a direct reflection of our vision, with a clear focus on growing beyond generics to provide pharmacists with innovative, value-added products, services and information to support their evolving business models and expanding role as front-line healthcare providers,” concluded Mr. Rai.
Concurrent with VANC’s new focus, the company will be reducing its generic portfolio over the next several months. Emerging opportunities in new healthcare sectors and the diminished ability to profit from generic sales drove this strategic decision. The realignment will provide existing products and services with increased focus and resources. This will also drive the expansion of a portfolio of high-margin over the counter (OTC) and point of care (POC) testing products and services that offer unique value to pharmacists, their patients, and consumers.
VANC is expanding its portfolio with announcements of strategic partnerships with Emerald, acquisition of the Corozon Platform, and plans to increase deployment of and expand offerings associated with HealthTab.
The recently announced strategic partnership with Emerald enables VANC to compete in the emerging medical cannabis sector with a line of endocannabinoid enhancers and with the potential to distribute medical cannabis to pharmacies when that avenue of sales is legalized.
“With a renewed focus on high-margin OTC/BTC product development, in addition to our recently announced partnership with Emerald Health, we anticipate generating increased sales and profitability in this pillar of the business in 2018,” explained Mr. Rai. “This shift in focus has also allowed us to engage with sales brokers across Canada, providing greater coverage to our products.”
The Corozon Platform, acquired in April 2018, offers a variety of functionalities including e-learning, e-commerce and potentially promotional modules. These capabilities ideally position it to serve as an anchor for this pillar of the business, functioning as an educational tool and distribution channel for a number of VANC products, including those the company will distribute for Emerald.
Mr. Rai added: “We will be able to leverage the Platform to promote our latest offerings and educate pharmacists on how to use them effectively. It will serve to drive our relationships with pharmacists and will also be a powerful retention tool. Through Corozon, we can efficiently market new services and products directly to the pharmacist.”
HealthTab will form the core of VANC’s future expansion of its point of care pharmacy screening tests to empower pharmacists and improve patient health. HealthTab as it is today will provide pharmacists with a platform to integrate precise blood chemistry into billable medicine reviews for patients in a timely and convenient manner.
“Our HealthTab service is based on a unique technology initially developed to provide a lab quality yet simple test for astronauts on the International Space Station. VANC can now provide this service to the general population. It will change how patients manage their health. It will also benefit the community by serving as a simple screening tool to detect serious conditions such as kidney failure or high cholesterol,” said Mr. Rai.
HealthTab systems have already been launched with strategic community pharmacy pilot programs in BC and Ontario. Furthermore, commitments for additional deployments have been secured and are scheduled for launch in Q2 2018. Additional tests to complement those currently offered by the HealthTab framework are in development and will make it best in class in terms of scope and accessibility to patients.
“The Emerald investment and licensing and the HealthTab and Corozon Platform acquisitions represent significant first steps in repositioning VANC. Further steps are being taken to create the structure and branding that will drive the evolution of our business to a new level in 2018,” concluded Mr. Rai.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing, and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director, and CEO
604-247-2639
info@vancpharm.com
www.vancpharm.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |